Here's what I wish someone had told me 6 years ago: the cheapest quote for medical supplies is almost never the cheapest option. Not when you factor in clinical outcomes, wound care protocol changes, and the hidden costs of switching suppliers mid-stream.
I'm the procurement manager at a 140-person regional healthcare network, and I've managed our wound care and surgical supply budget — roughly $180,000 annually — for the past 6 years. I've negotiated with 25+ vendors, tracked every invoice in our procurement system, and made every mistake you can make. Including the one where I nearly signed a contract that would have cost us an extra $12,000 in hidden fees.
When I first took over this role in 2019, I assumed the lowest unit price was the metric that mattered most. I'd compare Molnlycke Mepilex against competitors line by line, dollar by dollar. Three budget overruns and one supply chain crisis later, I learned about total cost of ownership (TCO).
Here's the thing about medical device procurement that most buyers don't talk about: the product cost is just the starting point. With Molnlycke — and honestly, with any major wound care or surgical brand — you're also paying for clinical support, training, supply chain reliability, and the cost of potential adverse events. That last one is huge, and it's almost never on the invoice.
My Initial Misjudgment: Price Per Dressing
In Q2 2022, I compared costs across 6 vendors for a 12-month supply of foam dressings. Vendor A quoted a mid-tier option at $4.20 per dressing. Vendor B quoted Mepilex at $5.80. I almost went with Vendor A until I calculated TCO:
- Vendor A's dressing needed changing every 2 days on moderate exudate wounds — 182 dressing changes per year per patient
- Mepilex with Safetac technology averaged 4 days between changes — 91 dressing changes per year per patient
- At 50 patients per year, that's 4,550 fewer dressing changes with Molnlycke
- Nursing time at $35/hour, 15 minutes per change: $39,812 saved annually in labor alone
That 'cheaper' option would have cost us more in nursing labor than the entire dressing budget. A 28% higher unit price translated to a 47% lower total cost.
The Hidden Costs No One Warned You About
After tracking 180+ orders over 6 years in our procurement system, I found that 34% of our 'budget overruns' came from one source: product switching costs. When we changed wound care protocols, it wasn't just the product price that changed. We had to retrain 12 nursing staff (each session cost us $240 in overtime), reprint 500 patient education sheets, and deal with a 6-week learning curve where complication rates temporarily spiked.
The conventional wisdom is that you should always get 3 quotes and go with the lowest. My experience with 200+ orders suggests that relationship consistency with a supplier like Molnlycke Healthcare US LLC often beats marginal cost savings, especially when you factor in clinical evidence and support.
Everything I'd read about medical device procurement said you should rotate vendors annually to keep pricing competitive. In practice, I found the opposite: our 3-year relationship with Molnlycke meant we got early access to product updates, dedicated clinical educator visits (saving us $3,000/year in external training), and priority supply allocation during the 2023 supply chain disruptions. Try putting a price tag on that.
What the 'Industry in Evolution' Means for Procurement
The medical supply industry in 2025 looks nothing like it did in 2019. Digital sourcing platforms have made price comparison easier, but they've also commoditized products that aren't commodities. A cardiac monitor might be a cardiac monitor on paper, but the clinical data behind Molnlycke's Mepilex vs. a generic foam dressing is not the same.
Five years ago, the standard practice was to bid out wound care contracts annually. Now, the smart networks I know are moving to 3-year agreements with performance clauses. Why? Because the cost of switching — in clinical outcomes, training, and supply chain risk — has become too expensive to ignore.
What was best practice in 2020 may not apply in 2025. The fundamentals haven't changed — you still need to manage costs — but the execution has transformed. We now track 'clinical TCO' alongside financial TCO. That means measuring average healing time, complication rates, and nurse satisfaction alongside price per unit.
The Boundaries of My Advice
That said, Molnlycke isn't the answer for every situation. In low-acuity wounds on healthy patients, a basic foam may be clinically adequate at a lower price point. For high-volume, low-complexity settings, a generic product might deliver acceptable outcomes. The key is knowing where the trade-off flips.
Also, I'm not saying you should never switch vendors. We switched our surgical glove supplier in 2024 and saved 18% on Biogel alternatives because the clinical difference was negligible for our OR's case mix. But we kept Molnlycke for wound care because the evidence supported the premium.
If you're evaluating electronic pipettes, prosthetic components, or other medical devices, the same principles apply: unit price is the starting line, not the finish line. Run the TCO numbers. Factor in training, reliability, clinical outcomes, and supply chain risk. And if a vendor can't — or won't — provide the data to calculate TCO, that's a red flag.
One more thing: don't take my word for it. The Agency for Healthcare Research and Quality (AHRQ) publishes guidance on total cost analysis in medical device procurement. Price your contract using their framework. That free setup offer from a competitor? It might cost you $4,500 in hidden fees, just like it almost did for us.
